COMPANY PROFILE

ReLive Biotechnologies

Explore full profile

A global regenerative medicine company targeting orthopedics/sports medicine, and plastic & reconstructive surgery

ChinaFounded 2021Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

At a glance

Status: Operational
Founded: 2021
Headquarters: China
Employees: 3
Open positions: None listed
Dealroom signal: 22.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Investment activity: 1 company, latest Jan 2023
Capital deployed: —
Preferred round: ACQUISITION
Links: LinkedIn

Founder mafia, market maps, research and news connected to this company by Dealroom

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jan 2023	$36M	$144M	Indaco Capital · Jiuyou Capital · Watson Investment · Shanghai Biomedicine Fund	↗
SEED✓Equity / VC	Feb 2022	$2.8M	$11M	Undisclosed	↗

ReLive Biotechnologies team growth

ReLive Biotechnologies's team grew 0% over the past year.

1-year team growth0%

Summary metrics are public; monthly history is available with a demoCompare with peers →

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MIMetrodora InstituteA medical and research center dedicated to advancing care and accelerating cures for people living with neuroimmune axis disorders	Salt Lake City, United States	Operational	39	$35M	$140M
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
SISPES Pharmaceuticals Inc.The company focuses on the research and development of improved specialty injectable products 505(b)(2)and complex generic drugs	United States	Operational
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
TRtranScripSpecialist pharmaceutical consultancy for the entire product lifecycle	Wokingham, United Kingdom	Acquired
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational